Just Injections to Lose Weight, Comes a New Pill that Loses up to 8% of Weight: Risks and Benefits of Orforglipron in the New Study

Il Fatto Quotidiano

Lean Left

Factuality

Ownership

After the overall success of semaglutide, a new molecule could soon enter the scene: orforglipron, a GLP-1 receptor agonist that, unlike the most well-known medicines in the same family, is taken as a tablet and not as an injection. The results of an international phase 3 clinical study published in The Lancet, conducted in 131 centers across the United States, Asia and Latin America in 1.